Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuromodulation: Three Start-Ups To Watch

This article was originally published in Start Up

Executive Summary

The neuromodulation market is growing at a rapid pace and investors and strategics are paying close attention to early-stage innovators. We highlight Cardionomic, Nuviant and Pixium, three young companies that are listening to the brain, fixing broken hearts and making the blind see.

You may also be interested in...



Neuromodulation Devices Stimulate Opportunities In Urology

Neuromodulation for urological indications, notably overactive bladder (OAB), has been dominated since the late 1990s by Medtronic’s sacral-nerve stimulation system InterStim, with the more recent addition of Cogentix Medical’s Urgent PC for tibial nerve stimulation. Yet only a fraction of OAB patients receive effective neuromodulation treatment, and several companies hope to lower barriers to this modality by developing alternative devices for urological indications.

Neuromodulation 2015: Innovation Expands Opportunities In Chronic Pain

In the market for neuromodulation devices, the largest opportunity is in the treatment of chronic pain, a condition that affects more than 1.5 billion people worldwide. Innovation is driving growth in this sector as companies develop next-generation neuromodulation technologies designed to improve outcomes, and resolve some of the problems with existing devices; these technologies will significantly expand the treatable population, and will allow companies both large and small to capture market share based on device efficacy and the strength of clinical evidence.

Second Sight Shows The Way

Second Sight secured FDA approval for the Argus II Retinal Prosthesis System in 2013 and followed it with an IPO, giving the company the capital necessary to expand the commercial launch of its system to restore the vision of patients blinded by retinitis pigmentosa while also developing a new system that might restore the vision of anyone who has lost their sight to disease. An interview with CEO Robert Greenberg, MD.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel